Analysis of seven GEO datasets confirmed elevated CTU2 expression in breast cancer (BRCA), colon adenocarcinoma (COAD), LIHC, non-small cell lung cancer (NSCLC) (Figures 1B–E), esophageal cancer (ESCA), KIRC, and adrenocortical carcinoma (ACC) (Supplementary Figures S1N–P). Here, CTU2 is linked to invasive breast carcinoma.